Search


Current filters:




Clear current filters  or Add more filters

View Option



Results 1-9 of 9 (Search time: 0.005 seconds).
  • previous
  • 1
  • next

  Postoperative dose-dense sequential chemotherapy with epirubicin, followed by CMF with or without paclitaxel, in patients with high-risk operable breast cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group (Journal article)

  Prognostic significance of HER-2, p53 and Bcl-2 in patients with epithelial ovarian cancer (Journal article)

  Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation (Journal article)

  Paclitaxel by 3-h infusion and carboplatin in anthracycline-resistant advanced breast cancer. A phase II study conducted by the Hellenic Cooperative Oncology Group (Journal article)

  Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group (Journal article)

  Dose-dense sequential adjuvant chemotherapy with epirubicin, paclitaxel and CMF in high-risk breast cancer (Journal article)

  Dose-dense sequential chemotherapy with epirubicin and paclitaxel versus the combination, as first-line chemotherapy, in advanced breast cancer: a randomized study conducted by the Hellenic Cooperative Oncology Group (Journal article)

  Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience (Journal article)

  Advanced stage mucinous epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience (Journal article)